ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 06, 2018
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 31, 2017
ProQR to Present at Scientific and Investor Conferences in September Press release LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 06, 2016
ProQR Announces Expert Perspectives Conference Call Series Press release Initial call in the series will feature Usher syndrome and retinitis pigmentosa on June 22 June 12, 2020
ProQR Announces R&D Day and Provides Update on Innovation Portfolio Press release First Investor R&D Day on March 14, 2016 in New York, NY November 30, 2015
ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients Press release LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 26, 2015
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day Press release LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2017
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2016
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates November 29, 2017
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis Press release LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. July 19, 2016